Pharmacokinetics of IS-5-MN after Oral and Intravenous Administration in Patients with Hepatic Failure

  • W. Akpan
  • R. Endele
  • G. Neugebauer
  • H. Steudel
Part of the International Boehringer Mannheim Symposia book series (BOEHRINGER)


Isosorbide-5-mononitrate (IS-5-MN) possesses complete absolute bioavailability due to the absence of any first-pass effect [1] in contrast to isosorbide dinitrate (ISDN) [2, 6,7, 8] which therefore has to be administered carefully in patients with impaired liver function, since higher concentrations than normal were found in these patients [4]. The aim of the present study was to evaluate the role of the liver in the fate of IS-5-MN and its two metabolites, isosorbide-5-mononitrate-2-glucuro-nide (IS-5-MN-2-glu) and isosorbide (IS). The results obtained in the liver patients were compared with those of a group of six healthy volunteers.


Liver Cirrhosis Renal Clearance None None Volunteer Group Impaired Liver Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abshagen U, Betzien G, Endele R, Kaufmann B (1981) Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol 20: 269–275PubMedCrossRefGoogle Scholar
  2. 2.
    Abshagen U, Betzien G, Endele R, Kaufmann B, Neugebauer G (1985) Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Eur J Clin Pharmacol (in press)Google Scholar
  3. 3.
    Betzien G, Kaufmann B, Schneider B, Ritschel WA (1985) Evaluating blood level curves: A comprehensive approach with KINPAK. Harvey Whitney, Cincinnati (in press)Google Scholar
  4. 4.
    Bogaert MG (1983) Clinical pharmacokinetics of organic nitrates. Clin Pharmacokinet 8: 410–421PubMedCrossRefGoogle Scholar
  5. 5.
    Endele R, Senn M (1983) MS/MS in pharmacokinetic studies. Int J Mass Spectrometry Ion Physics 48: 81–84CrossRefGoogle Scholar
  6. 6.
    Morrison RA, Wiegand UW, Jähnchen E, Höhmann D, Bechtold H, Meinertz T, Fung H-L (1983) Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. Clin Pharmacol Ther 33: 747–756PubMedCrossRefGoogle Scholar
  7. 7.
    Platzer R, Reutemann G, Galeazzi RL (1982) Pharmacokinetics of intravenous isosorbide-dinitrate. J Pharmacokinet Biopharm 10: 575–585PubMedCrossRefGoogle Scholar
  8. 8.
    Taylor T, Chausseaud LF, Doyle E, Bonn R, Darragh A, Lambe R (1982) Isosorbide dinitrate pharmacokinetics. Arzneimittelforsch 32: 1329–1333PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • W. Akpan
  • R. Endele
  • G. Neugebauer
  • H. Steudel

There are no affiliations available

Personalised recommendations